Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery
Dr Shivkumar Kalyanaraman emphasizes need for quality research, partnerships, and measurable outcomes
Subscribe To Our Newsletter & Stay Updated
